WEBULL
WebtradeDownload

CARsgen Therapeutics Holdings (SEHK:2171) Gains On CT0596 IND Clearance, But Is The Valuation Too Rich

Simply Wall St · 2d ago

CARsgen Therapeutics Holdings (SEHK:2171) has drawn fresh attention after its allogeneic CAR T-cell candidate CT0596 received IND clearance from China’s National Medical Products Administration for relapsed or refractory multiple myeloma.

See our latest analysis for CARsgen Therapeutics Holdings.

The CT0596 IND clearance arrives as CARsgen Therapeutics Holdings trades at HK$14.7, with a 1 day share price return of 2.15% and a 90 day share price return down 16.62%. The 1 year total shareholder return has declined 34.43%, while the 3 year total shareholder return remains positive at 55.39%, suggesting longer term holders have seen mixed but at times stronger momentum than in recent months.

If CARsgen’s progress in cell therapies has caught your attention, you may want to broaden your watchlist with other healthcare focused AI opportunities through the 129 healthcare AI stocks.

After CT0596’s clearance and the recent share price bounce, the choice is stark. Do you treat CARsgen Therapeutics Holdings as an early entry opportunity today, or wait for a clearer valuation picture before committing fresh capital?

Preferred Price-to-Book Multiple of 9.6x: Is It Justified?

CARsgen Therapeutics Holdings currently trades on a P/B of 9.6x, which is high relative to peers. That multiple is being applied to a stock at HK$14.7 that has delivered a 1 year total shareholder return that declined 34.43% and a 5 year total shareholder return that declined 53.41%.

The P/B ratio compares a company’s market value to its book value. It is often used for asset heavy or early stage businesses where earnings are not yet a reliable guide. For CARsgen Therapeutics Holdings, which remains unprofitable with a reported net loss of CN¥97.861 million, the focus falls on the balance sheet and investors’ expectations rather than on current profits.

At 9.6x book value, the market is paying a premium compared with the peer average of 3.6x. That gap suggests investors are pricing in stronger prospects for CAR T-cell therapies and the existing product and pipeline suite, including Zevor cel for relapsed or refractory multiple myeloma and various autologous and allogeneic candidates at different clinical stages.

The comparison with the wider Hong Kong Biotechs industry is also clear. CARsgen Therapeutics Holdings trades on a P/B of 9.6x, while the industry average stands at 3.6x. This indicates a materially richer valuation than both direct peers and the broader sector, even though the company is currently unprofitable and has underperformed the Hong Kong market and the Hong Kong Biotechs industry over the past year in total return terms.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Price-to-book of 9.6x (OVERVALUED).

However, CARsgen Therapeutics Holdings still faces clinical and regulatory uncertainty across its pipeline, and any delay or setback could pressure sentiment around that premium P/B.

Find out about the key risks to this CARsgen Therapeutics Holdings narrative.

Next Steps

Given that the tone around CARsgen Therapeutics Holdings is mixed, it makes sense to move quickly and review the data first hand so you can decide where you stand on its 2 key rewards through the 2 key rewards.

Looking for more investment ideas beyond CARsgen Therapeutics Holdings?

Do not stop with CARsgen Therapeutics Holdings. Broaden your options now with a few focused stock ideas that match different investing styles and risk levels.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.